NCT07243964 Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation
| NCT ID | NCT07243964 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chang Chen |
| Condition | Lung Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 244 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 244 participants in total. It began in 2025-11-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
By establishing a prospective, multicenter lung transplantation clinical cohort, this study aims to systematically evaluate the utility of cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomics in monitoring and predicting graft dysfunction after lung transplantation, and to develop a multi-omics predictive model for early identification, dynamic monitoring, and mechanistic investigation of acute lung allograft dysfunction (ALAD) and chronic lung allograft dysfunction (CLAD).
Eligibility Criteria
Inclusion Criteria: 1. Recipients aged ≥18 years undergoing single or double lung transplantation; 2. Postoperative recipients capable of understanding and providing written informed consent, and willing to comply with scheduled follow-ups and sample collections as required by the study; 3. Postoperative recipients clinically assessed as stable and eligible for routine follow-up and hematological examinations; 4. Recipients able to undergo dynamic pulmonary function monitoring during follow-up; 5. No planned participation in other interventional trials during the study period that may impact immune function or pulmonary function; 6. Retransplant patients will be considered as a new transplant event and may be included in the analysis. Exclusion Criteria: 1. History of active malignancy or presence of untreated malignancy within 5 years prior to transplantation; 2. Presence of active systemic infection or significant immune rejection; 3. Female patients who are pregnant or lactating; 4. Any other condition deemed by the investigator to be inappropriate for inclusion .
Contact & Investigator
Chang Chen, MD,PHD
PRINCIPAL INVESTIGATOR
Shanghai Pulmonary Hospital, Shanghai, China
Frequently Asked Questions
Who can join the NCT07243964 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07243964 currently recruiting?
Yes, NCT07243964 is actively recruiting participants. Contact the research team at wujunqi@tongji.edu.cn for enrollment information.
Where is the NCT07243964 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07243964 clinical trial?
NCT07243964 is sponsored by Chang Chen. The principal investigator is Chang Chen, MD,PHD at Shanghai Pulmonary Hospital, Shanghai, China. The trial plans to enroll 244 participants.